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Introduction:  Rituximab  (RTX)  is  a monoclonal  anti-CD20  antibody  approved  for the  treatment  of  rheuma-
toid arthritis  (RA)  in  association  with  methotrexate  (MTX).
Objectives:  To evaluate  the  efﬁcacy  and  safety  of  RTX–MTX  combination  therapy  compared  with RTXPlease cite this article in press as: Sebastiani M, et al. Efﬁcacy and safety of rituximab with and without methotrexate in the treatment of
rheumatoid arthritis patients: Results from the GISEA register. Joint Bone Spine (2014), http://dx.doi.org/10.1016/j.jbspin.2014.06.011
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alone  in the  treatment  of RA.
Methods:  We  analyzed  data  from  a prospective  cohort  study,  the  Italian  biologic  register  GISEA, to
investigate  the  efﬁcacy  and  safety  of  rituximab.  Moreover,  the  adverse  events  (AE) and  the  causes  of
discontinuation  therapy  were  analyzed.
Results:  We  identiﬁed  338  RA  patients,  162  treated  with  RTX  and  176  with  RTX–MTX.  After  52 and
104  weeks  of  therapy  the  disease  activity  score  in  28  joints  and  the Health  Assessment  Questionnaire
Score  were  available  in 168  patients  (78  with RTX–MTX  and  60 with  RTX  alone),  showing  signiﬁcant
reduction  without  differences  among  the  two groups.  AE  were  reported  in 142 patients  (42%),  for a  total
∗ Corresponding author. Rheumatology Unit, Department of Internal Medicine, University of Modena and Reggio Emilia, Via del Pozzo, 71, 41121, Modena, Italy.
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of 368  recorded  side  effects.  The  majority  (90.5%)  of  AE  were  mild  to  moderate  in severity.  Comparable
percentages  of  severe  AE  were  reported  in  the  2  groups  (9.9%  for  RTX  alone  and  9.3%  for  RTX  +  MTX).
A poor  disease  control  was  observed  in  14.2%  and  13.5%  of patients  treated  with  RTX  + MTX  and  RTX,
respectively;  while  12 patients  (4.5% in  RTX  + MTX,  and  2.5%  in RTX group)  suspended  therapy  for  AE.
Conclusions:  RTX  showed  a good  efﬁcacy  and  safety  proﬁle  in the real-life  management  of RA  patients
regardless  of  the  association  with  MTX.
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. Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease
haracterized by joint inﬂammation, which affects approximately
.5% of the adult population in Italy [1,2].
Despite methotrexate (MTX) remains the cornerstone of RA
reatment, the introduction of TNF inhibitors has led to a consid-
rable improvement in the management of this disease. However,
n 30% of the patients, treatment has to be discontinued because of
nefﬁcacy, non-response or undesirable side effects [3–8].
Hence, other biotherapeutic agents, with different targets, have
merged. The co-stimulatory inhibitor abatacept and the anti-
L-6 tocilizumab, in combination with methotrexate (MTX), are
icensed for moderate to severe active RA in adults responding
nadequately to previous therapy with one or more conventional
isease-modifying drugs (DMARDs). Tocilizumab is also licensed as
onotherapy in patients intolerant of MTX. In addition, the anti-B-
ell therapy rituximab (RTX), in combination with MTX, is licensed
n patients with severe active RA with inadequate response or intol-
rance to other DMARDs including one or more TNF- inhibitors
9,10].
In a signiﬁcant proportion of RA patients, these novel biothera-
eutic agents, including RTX, are employed because of the failure
f conventional DMARDs and contraindications to anti-TNF agents.
With the exception of the ﬁrst randomized trial [3], RTX
s usually associated with MTX. Sometimes, however, MTX  is
ontraindicated or may  cause undesirable adverse events, and
herefore cannot be administered [11].
Therefore, the aim of this study was to analyze the safety and
fﬁcacy of RTX in daily practice in RA patients in association with
TX  or in monotherapy, using data from the GISEA (Italian Group
or the Early Arthritis Study) Register.
. Methods
The nationwide GISEA registry, which started in 2008, includes
atients under biotechnological DMARDS dating back to 1999,
nd prospectively all patients since 2008 [12]. Data records and
onitoring of rheumatic patients treated with biological drugs at
ospital and community-based Rheumatology Units throughout
taly were consecutively included. For the aim of the present study,
e considered only RA patients classiﬁed according the ACR/EULAR
010 criteria undergoing RTX treatment [13].
At the entry in the database, age, sex, disease duration, intake of
lucocorticoids and DMARDs, and the presence of co-morbidities
anxiety/depression, cardiopathy, cerebrovascular diseases, dia-
etes, arterial hypertension, liver diseases, lung diseases, neoplasia,
ephropathy, and peripheral vasculopathy) were collected. In addi-
ion, C-reactive protein (CRP mg/L), erythrocyte sedimentation rate
ESR), rheumatoid factor (RF), anti-cyclic citrullinated peptidesPlease cite this article in press as: Sebastiani M,  et al. Efﬁcacy and safet
rheumatoid arthritis patients: Results from the GISEA register. Joint B
CCP) were recorded; every 6 months of therapy, 4 variables-
isease activity score on 28 joints (ESR-based DAS28), Health
ssessment Questionnaire (HAQ), and any switch to another bio-
ogical drug were also recorded [14]. Data concerning changes in Elsevier  Masson  SAS on  behalf  of  the  Société  Française  de  Rhumatologie.
treatment, disease activity and the occurrence of adverse events
are captured every 6 months.
The duration of treatment was considered until 2 months after
the last RTX infusion or at the time of beginning another biologic.
The Mann–Whitney and Wilcoxon non-parametric test, Pear-
son’s chi2 test and Fisher’s exact test were used to evaluate the
differences in continuous and categorical variables between the
two groups. All of the analyses were made using SAS version 9.2
(SAS Institute, Inc; Cary, NC), and a P value of 0.05 or less was
considered statistically signiﬁcant [15].
3. Results
A total of 338 patients were identiﬁed, 176 treated with
RTX + MTX  (mean dosage of MTX  11.45 ± 3.3 mg  weekly), and 162
with RTX without DMARDs (clinical and demographic features
of patients are reported in the Table 1). RTX was administered
in monotherapy primarily for previous adverse events or intoler-
ance to MTX. The two  groups of patients were similar in terms of
demographic parameters, baseline disease features, and previous
DMARDs/biologic treatments, with the exception of signiﬁcantly
longer disease duration in those undergoing RTX alone (Table 1).
More than 92% of patients were Caucasian, only a low percentage
was Asiatic, African or Afro-American.
Moreover, 53.3% of patients were taking a low dose of corticos-
teroids (mainly, prednisone 5–10 mg  daily): in particular, 72.8% of
patients in RTX group, and 35.2% in RTX + MTX  group (P ≤ 0.0001).
Co-morbidities were frequently recorded, equally distributed in
the two  groups; in particular, 210 patients (62.1%) showed car-
diovascular disorders (arterial hypertension in 20.25% of all cases),
thyroid abnormalities (8.8%), diabetes (4.5%), and/or gastropathies
(3.9%).
A cancer preceding or present at the beginning of RTX was
recorded in 13 cases; namely, in 9 patients, the malignancy pre-
ceded the anti-CD20 treatment (mean 10.4 years before RTX; range
1–18, 5 in RTX + MTX  group and 4 RTX group), while in 4 a non-
Hodgkin’s lymphoma was  observed at the same time of RTX starting
(2 patients in both groups).
Of interest, complicating malignant disorders were observed
during treatment with RTX in 5 patients, almost all were treated
with the combination therapy (two cervical uterine cancer, one
bladder cancer, and one breast cancer). On the contrary, no relapse
of previous neoplastic disorders was observed during RTX treat-
ment.
3.1. Efﬁcacy outcomes
One hundred and sixty-eight patients were available for evalua-
tion after 24 months of follow-up (90 treated with RT–MTX therapy
and 78 with RTX monotherapy), 77 patients withdrawal therapy
before 2 years, the others showed a shorter follow-up or missingy of rituximab with and without methotrexate in the treatment of
one Spine (2014), http://dx.doi.org/10.1016/j.jbspin.2014.06.011
data or were lost to follow-up.
RTX were administered at the dosage of 1 g on alternate weeks
for 2 infusions every 6 months in 87.4% of patients, 7.3% were
treated annually, and 5.3% of patients were treated on demand,
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Table  1
Clinico-serological features of patients treated with rituximab.
Total RTX RTX + MTX  P
Number of patients 338 176 162
Sex  (male/female) 45/293 26/150 19/143 NS
Mean  age (years ± SD) 54.8 ± 12.8 55.4 ± 12.1 54.3 ± 13.4 NS
Mean  follow-up (months ± SD) 25.4 ± 14.7 26.3 ± 15.2 24.1 ± 14.3 NS
Disease  duration (years ± SD) 10.7 ± 7.8 11.7 ± 8.0 9.8 ± 7.4 0.026
DAS28  5.47 ± 1.43 5.35 ± 1.44 5.58 ± 1.42 NS
HAQ  1.50 ± 0.82 1.50 ± 0.85 1.51 ± 0.79 NS
Previous  DMARDs (n ± SD) 2.4 ± 1.7 2.6 ± 1.6 2.2 ± 1.7 NS
Rheumatoid factor (%) 74.6 77.6 70.1 NS
Anti-CCP (%) 61.2 65.8 56.8 NS
Body  mass index (± SD) 25.3 ± 5.3 24.6 ± 5.0 25.9 ± 5.6 NS
Glucocorticoids (%) 53.2 72.9 35.2 ≤ 0.001
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gTX: rituximab; MTX: methotrexate; anti-CCP: anti-ciclic citrullinated peptides; DA
igniﬁcant.
ith a cycle of 2 infusion of RTX only when a relapse of disease was
bserved. No differences in modalities or interval of administration
f the drug were recorded in the 2 groups.
DAS28 evaluated at week 52–104 showed signiﬁcant improve-
ent from baseline in both groups (P ≤ 0.002. Fig. 1). Comparable
ariations were observed in patients assuming steroid therapy.
ikewise, no differences were observed in HAQ; in all groups an
mprovement was observed after the ﬁrst 52 weeks, while a mild
ncrease of HAQ was present in the next 52 weeks (see Fig. 1).
he mean variation of DAS28 after 52 weeks was  1.61 ± 0.64 in
TX–MTX group and 1.48 ± 0.59 in RTX group (P not signiﬁcant).
inally, remission of RA (DAS28 < 2.6) was achieved in 17.9% and
0.3% of patients treated or not with MTX, respectively (P not sig-
iﬁcant). A reduction in the mean daily dosage of glucocorticoidsPlease cite this article in press as: Sebastiani M, et al. Efﬁcacy and safety
rheumatoid arthritis patients: Results from the GISEA register. Joint B
as observed in 28% of patients (6.65 ± 5.0 mg  daily at baseline
nd 5.0 ± 1.9 mg at the end of follow-up; P not signiﬁcant); in 7% of
atients steroids were stopped. However, no signiﬁcant differences
ere observed in DAS28 reduction in patients taking or not steroids
ig. 1. DAS28 and HAQ in 168 patients treated with rituximab. Variation of mean
isease activity score calculated on 28 joints (DAS28) and Health Assessment Ques-
ionnaire in patients treated with rituximab (RTX) with or without methotrexate
MTX). Reduction of DAS28 and HAQ over the time was  signiﬁcant in all group both
fter  52 and 104 weeks (P ≤ 0.002). The mean variation of DAS28 after 52 weeks
as  1.61 ± 0.64 in RTX–MTX group and 1.48 ± 0.59 in RTX group (P not signiﬁcant),
hile the reduction of HAQ was 0.43 ± 0.18 and 0.39 ± 0.21 in RTX–MTX and RTX
roup, respectively (P not signiﬁcant).isease Activity Score on 28 joints; HAQ: Health Assessment Questionnaire; NS: not
(5.53 vs 3.7 and 5.67 vs 3.79 at baseline and after 24 months in RTX
and RTX + steroids groups, respectively).
No differences between the two  groups were observed with
regard the basal values of body mass index (BMI) and the response
to the drugs after 6, 12, and 24 months of follow-up.
3.2. Safety outcomes
Overall, 142 patients (42%) reported at least one adverse event
(AE), 58 in RTX group and 84 in RTX–MTX (P = 0.027) at any time
during the follow-up period, for a total of 368 recorded AE, and a
rate of 51.4 AE/100 patient-years (31.4 and 76.2/100 patients/year,
respectively, P ≤ 0.001). The most frequently reported AE in each
treatment group are shown in Table 2. The majority (90.5%) of
AE was mild to moderate in severity; despite the relative risk
of severe AE in RTX–MTX was  2.29, the proportion of severe
adverse events was similar in each group (9.9% of AE were clas-
siﬁed as severe in patients receiving RTX and 9.3% in patients in
the RTX + MTX  groups). Statistically signiﬁcant differences were
observed between the two groups in the overall frequency of
AE; a higher proportion of AE were recorded in RTX + MTX  group
compared to RTX alone, with the 67% of the overall observed
AE in RTX–MTX group. Moreover, 47.7% of patients in RTX–MTX
group developed at least one AE vs 35.8% in RTX group (P = 0.027);
while comparable percentages of patients with severe events were
observed in each group (9.3% of patients receiving RTX alone and of rituximab with and without methotrexate in the treatment of
one Spine (2014), http://dx.doi.org/10.1016/j.jbspin.2014.06.011
9.9% of patients in the RTX + MTX). Of interest, with regard to the
corticosteroid therapy AE were observed in 58.9% and 22.8% of
patients assuming or not steroids, respectively (P < 0.0001).
Table 2
Adverse events per 100 patients-year in patients treated with rituximab.
Total RTX RTX + MTX  P
Adverse events 51.4 31.4 76.2 ≤ 0.001
Cardiovascular events 3.9 2.6 5.5 NS
Infections 20.2 9.3 33.6 0.001
Cancer 0.7 0.2 1.2 NS
Infusional reactions 7.9 7 9.2 NS
Gastroentherologic events 5.2 3.1 7.7 NS
Haematologic events 2.8 2.8 2.8 NS
Ginecologic events 0.6 0.2 0.9 NS
Neurological events 1 0.3 1.2 NS
Otorhinolaryngoiatric events 2.5 2.1 3.1 NS
Other 6.6 3.1 10.8 ≤ 0.001
Severe adverse events (%) 4.9 3.1 7.1 0.01
Infections (%) 1.8 1 2.8 0.04
Infusional reactions (%) 1.8 1.6 2.2 NS
Other (%) 1.2 0.5 2.2 NS
RTX: rituximab; MTX: methotrexate; NS: not signiﬁcant.
ARTICLE IN PRESSG ModelBONSOI-4060; No. of Pages 5
4 M. Sebastiani et al. / Joint Bone Spine xxx (2014) xxx–xxx
Table 3
Cause of discontinuation of rituximab therapy.
Total (77 patients)
n  (%)
RTX (35 patients)
n (%)
RTX + MTX  (42 patients)
n (%)
P
Adverse events 12 (15.6) 4 (11.4) 8 (19.0) NS
Efﬁcacy loss 19 (24.7) 9 (25.7) 10 (23.8) NS
Inefﬁcacy 28 (36.4) 13 (37.1) 15 (35.7) NS
Disease remission 5 (6.5) 0 (0) 5 (11.9) NS
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TX: rituximab; MTX: methotrexate; NS: not signiﬁcant.
.2.1. Infection-related adverse events
Adverse events classiﬁed as infections were signiﬁcantly higher
n RTX + MTX  group (33.6 cases/100 patients/year, respectively,
ompared with 9.3 infections/100 patients/year in RTX group,
 = 0.001), with recurrent infections in the same patients. In this
egard, about half of patients who suffered one severe infection
ere reported as having a second severe infection during the sub-
equent follow-up. The type and severity of infections were similar
mong the two groups, i.e. (respiratory tract infections, urinary
ract infections, and nasopharyngitis were the most common). A
igher rate of serious infections was reported in RTX–MTX group,
espite the same percentage of severe infections was  recorded in
he two groups, 4/121 (3.3%) and 9/247 (3.6%), in RTX and RT–MTX
roups, respectively; these events resolved without sequelae. The
se of steroids did not signiﬁcantly increase the number of patients
ith infectious AE (17.2% vs 11.4% of patients taking or not steroids,
espectively), but, similarly to MTX, a higher number of infective AE
ere observed in patients treated with steroids.
.2.2. Acute infusion reactions
Symptoms and/or signs suggesting an acute infusion reaction
pruritus, fever, urticaria/rash, pyrexia, sneezing, throat irritation,
ough and bronchospasm, hypotension, or hypertension) were
eported in a total of 57 patients, without differences between the
 groups; on the other hand, in patients treated with RTX alone,
e observed a higher number of infusion-related reactions, with
ecurrent episodes in the same patients, regardless of the asso-
iation of RTX with steroids (15.1% and 17% in patients with and
ithout associated steroids, respectively).
.3. Withdrawal of therapy
During a follow-up period of 74.2 ± 8.9 weeks, 77 patients
22.8%) suspended RTX therapy; among them, 42 patients belonged
o RTX + MTX  group (23.9%), and 35 to RTX group (21.6%), without
igniﬁcant differences between the two groups (P = 0.348).
The causes of treatment discontinuation were an insufﬁcient
herapeutic response in 47 patients, in particular a primary inefﬁ-
acy was observed in 28 patients, while in 19 patients a secondary
oss of efﬁcacy was registered. On the contrary, in 5 patients, all in
TX + MTX  group, the treatment was stopped for the disease remis-
ion; in 12 cases, an AE caused the treatment discontinuation (see
able 3).
. Discussion
The present study demonstrates the efﬁcacy and safety of RTX in
he real-life treatment of RA patients, regardless of the association
ith MTX. These results are rather relevant given the signiﬁ-
antly longer mean disease duration, the lower rate of AE, and/or
nfections in patients treated with RTX alone compared to the com-Please cite this article in press as: Sebastiani M,  et al. Efﬁcacy and safet
rheumatoid arthritis patients: Results from the GISEA register. Joint B
ination RTX–MTX.
Rituximab is currently prescribed as a second line treatment of
ctive RA in association with methotrexate. However, in daily prac-
ice, RTX can be administered without methotrexate in patients4 (9.5) NS
with intolerance or previous AE to this drug [4]. In the present
register-based study we  evaluated the clinical outcomes of RA
patients undergoing treatment with RTX associated or not to MTX.
Nevertheless, in the clinical practice biologic, drugs were often used
as monotherapy or associated with a DMARD different by MTX. [16].
In several randomized trials, the efﬁcacy of RTX has been
demonstrated in patients before and after TNF inhibitors [3,17].
Three other observational studies in RA patients on the use of
RTX in monotherapy have been reported, with a total of 89 patients
treated with RTX alone [18–21].
In the randomized trial, the efﬁcacy of RTX alone was compared
with the association RTX + MTX. The study included a total of 161
RA patients with 40 subjects in the monotherapy group, showing no
difference in EULAR response between two groups (85% of respon-
der in patients treated with RTX alone vs 83% in RTX + MTX  group)
[18]. In the expansion of Edwards’ study, Strand et al. [21] found
RTX to be useful only in the RTX + MTX  group, suggesting the syn-
ergistic effect of this association. Solau-Gervais et al. [19] did not
conﬁrm these ﬁndings since they found that the interval to retreat-
ment was, paradoxically, longer in RTX monotherapy patients than
in RTX + MTX  patients. Owczarczyk et al. [20] evaluated a total of 40
patients with active RA. Twenty patients received RTX as monother-
apy having previously failed or being intolerant to MTX, while 20
patients continued to receive also MTX  throughout the study. The
authors concluded that monotherapy with rituximab was effective
in RA patients in whom treatment with MTX  is precluded due to
intolerance or contraindications. RTX monotherapy showed good
or moderate EULAR responses in the majority of patients, without
differences in the frequency of infusion reactions or infections.
Safety of RTX was carefully analyzed by Edwards et al.
[18] in their study. The treatment groups (RTX, RTX + MTX  or
RTX + cyclophosphamide) had a similar overall incidence of adverse
events, with 73 to 85% of patients reporting at least one event, while
no signiﬁcant differences were observed also for severe adverse
events. Moreover, human anti-chimeric antibodies developed in
only 5 of 117 patients (4.3 percent) treated with RTX.
The present registry-based study showed a good efﬁcacy for RTX
with a mean reduction of DAS28 to 52 weeks of more than 1.50
points, with maintenance after two  years. No signiﬁcant differences
were observed for patients treated or not with MTX  both for mean
DAS28 and HAQ variation and achievement of disease remission.
The registry data does not allow us to evaluate the efﬁcacy of RTX on
some serological parameters, such as rheumatoid factor positivity,
previously reported [17,21,22].
Discordant data were reported from other large cohort studies.
For example, in German register RABBIT, patients without MTX  or
leﬂunomide co-medication yield less favorable responses [23]. On
the contrary, similarly to our results, in the other German register
GERINIS, about 20% of patients were treated in monotherapy with-
out signiﬁcant differences if compared with patients assuming MTX
or leﬂunomide [24].y of rituximab with and without methotrexate in the treatment of
one Spine (2014), http://dx.doi.org/10.1016/j.jbspin.2014.06.011
The overall safety proﬁle of RTX observed in our patients’ pop-
ulation was  consistent with that previously reported in patients
with either lymphoma or rheumatoid arthritis [10,17–21,25]. Of
interest, the number of patients presenting AE in the two groups
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s similar, although the rate of infections is signiﬁcantly higher in
atients treated with RTX–MTX, and a higher incidence of infu-
ional reactions is observed in patients with RTX monotherapy; so,
lthough severe reactions were rare, a peculiar attention should be
eserved to patients with recurrent episodes of infectious or infu-
ional AE. Steroids do not seem to add any further advantage in
fﬁcacy of RTX, while they increase the overall rate of AE, in partic-
lar the infections. So, steroids should be associated to the standard
herapy only in selected patients; in particular, steroids should be
voided in patients with higher infectious risk.
Otherwise lymphoproliferative disorders [26], RTX is admin-
stered in RA at the standard dosage of 1 g given 2 weeks apart
very six months; we could speculate a different efﬁcacy of the
rug according to BMI. Of interest, no signiﬁcant differences were
bserved in clinical response to RTX with regard to BMI  in our
opulation, conﬁrming the few published data [27]. Since 17.1%
f our patients had a BMI  ≥ 30, this result could be translated into
 substantial cost savings without signiﬁcant variation in clinical
fﬁcacy.
Potential limitations of our study include all bias related to
bservational registry cohort studies. Concerning the number of
revious anti-rheumatic treatments, we cannot exclude under-
eporting, and available data did not allow any adjustment (for
xample, we  cannot calculate the interval between RTX admin-
stration). Clinical, serologic and demographic data were present
n more than 75% of patients. Obviously, we  cannot exclude an
nderestimation of adverse events and concurrent therapies.
Although this is a registry-based observational study, our data
eem to demonstrate the efﬁcacy of RTX independently of the
ssociation with MTX  in a large series of RA patients; the possi-
le relevance of these ﬁndings in clinical practice is reinforced by
he higher rate of AE observed in patients treated with combined
TX–MTX therapy, and should be deﬁnitely conﬁrmed by further
andomized double-blind studies.
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